Inflammatory fibrous histiocytoma: an important variant of malignant fibrous histiocytoma highly responsive to chemotherapy.

Abstract

Inflammatory fibrous histiocytoma is a recently recognized variant of malignant fibrous histiocytoma. Patients managed with surgical excision or radiation therapy usually have had multiple recurrences, often with metastases. The disease is insidious but ultimately fatal. Four consecutive patients were treated with inflammatory fibrous histiocytoma with alkylating agents with or without anthracyclines and produced prolonged and sustained remissions. Inflammatory fibrous histiocytoma may be another highly chemotherapeutically responsive tumor that deserves active case identification for aggressive curative therapy.

• Authors: M C Poon, J R Durant, M J Norgard, V Y Chang-Poon
• Journal: Annals of internal medicine (Ann Intern Med) Vol. 97 Issue 6 Pg. 858-63 (Dec 1982) ISSN: 0003-4819 [Print] United States
• PMID: 6293357 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Procarbazine
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Adolescent
• Adult
• Aged
• Antineoplastic Agents (administration & dosage)
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Drug Therapy, Combination
• Female
• Histiocytoma, Benign Fibrous (drug therapy, pathology)
• Humans
• Male
• Middle Aged
• Prednisone (administration & dosage)
• Procarbazine (administration & dosage)
• Vincristine (administration & dosage)